Interaction energy analyses of folate analog binding to human dihydrofolate reductase: Contribution of the antifolate substructural regions to complex stability

Drug Metabolism and Drug Interactions

Volumn 16, Issue 2, 2000, Pages 99-122

  Pitts, Conrad ^a   Bowen, Donnell ^a   Southerland, William M ^a  

^a HOWARD UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Antifolate substructural regions; Binding energies; Complex stability; Human dihydrofolate reductase

Indexed keywords

DIHYDROFOLATE REDUCTASE; FOLIC ACID DERIVATIVE; METHOTREXATE; WATER;

ARTICLE; COMPLEX FORMATION; DRUG BINDING SITE; DRUG PROTEIN BINDING; DRUG STRUCTURE; ENZYME BINDING; HUMAN; NONHUMAN; STRUCTURE ANALYSIS;

EID: 0033927192     PISSN: 07925077     EISSN: None     Source Type: Journal    
DOI: 10.1515/DMDI.2000.16.2.99     Document Type: Article

References (15)

1. Huennekens FM. The methotrexate story: a paradigm for development of cancer chemotherapeutic agents. Adv Enzyme Regul 1994; 34: 397-419.
2. Williams JW, Morrison JF, Duggleby RG. Methotrexate, a high-affinity pseudosubstrate of dihydrofolate reductase. Biochemistry 1979; 18: 2567-2573.
3. Rosowsky A, Forsch RA, Moran RG, Kohler W, Freisheim JH. Methotrexate analogues. 32. Chain extension, alpha-carboxyl deletion, and gamma-carboxyl replacement by sulfonate and phosphonate: effect on enzyme and cell-growth inhibition. J Med Chem 1988; 31: 1326-1331.
4. Rosowsky A, Bader H, Radike-Smith M, Cucchi CA, Wick MM, Freisheim JH. Methotrexate analogues. 28. Synthesis and biological evaluation of new gamma-monoamides of aminopterin and methotrexate. J Med Chem 1986, 29: 1703-1709.
5. Rosowsky A, Forsch RA, Yu CS, Lazarus H, Beardsley GP. Methotrexate analogues. 21. Divergent influence of alkyl chain length on the dihydrofolate reductase affinity and cytotoxicity of methotrexate monoesters. J Med Chem 1984; 27: 605-609.
6. McGuire JJ, Russell CA, Bolanowska WE, Freitag CM, Jones CS, Kalman TI. Biochemical and growth inhibition studies of methotrexate and aminopterin analogues containing a tetrazole ring in place of the gamma-carboxyl group. Cancer Res 1990; 50: 1726-1731.
7. Whitehead VM. Synthesis of methotrexate polyglutamates in L1210 murine leukemia cells. Cancer Res 1977; 37: 408-412.
8. Galivan J. Transport and metabolism of methotrexate in normal and resistant cultured rat hepatoma cells. Cancer Res 1979; 39: 735-743.
9. Kumar P, Kisliuk RL, Gaumont Y, Nair MG, Baugh CM, Kaufman BT. Interaction of polyglutamyl derivatives of methotrexate, 10-deazaaminopterin, and dihydrofolate with dihydrofolate reductase. Cancer Res 1986; 46: 5020-5023.
10. Rosowsky A, Wright JE, Vaidya CM, et al. Synthesis and potent antifolate activity and cytotoxicity of B-ring deaza analogues of the nonpolyglutamatable dihydrofolate reductase inhibitor N-alpha-(4-amino-4-deoxypteroyl)-N-delta-hemiphthaloyl-L-ornithine. J Med Chem 1998; 41: 5310-5319.
11. DeGraw JL, Christie PH, Kisliuk RL, Gaumont Y, Sirotnak FM. Synthesis and antifolate properties of 9-alkyl-10-deazaminopterins. J Med Chem 1990; 33: 212-215.
12. Sirotnak FM, Schimid FA, Otter GM, Piper JR, Montgomery JA. Structural design, biochemical properties, and evidence for improved therapeutic activity of 5-alkyl derivatives of 5-deazaaminopterin and 5-deazamethotrexate compared to methotrexate in murine tumor models. Cancer Res 1988; 48: 5686-5691.
13. Piper JR, Ramamurthy B, Johnson CA, Otter GM, Sirotnak FM. Analogues of 10-deazaaminopterin and 5-alkyl-5-10-dideazaaminopterin with the 4-substituted 1-naphthoyl group in the place of 4-substituted benzoyl. J Med Chem 1996; 39: 614-618.
14. Cody V, Luft JR, Ciszak E, Kalman TI, Freishein JH. Crystal structure determination at 2.3 Å of recombinant human dihydrofolate reductase ternary complex with NADPH and methotrexate-gamma-tetrazole. Anti-Cancer Drug Design 1992; 7: 483-491.
15. Brooks BR, Bruccoleri RE, Olafson BD, States DJ, Swaminathan S, Karplus M. CHARMM: a program for macromolecular energy, minimization, and dynamics caluclations. J Comput Chem 1983; 4: 187-217.